Q-omics provides the consensus-scored ZNF718 profile across patient tissues and cancer cell-line models. ZNF718 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF718 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, ZNF718 RNA expression shows 18,312 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where ZNF718 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF718 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF718 survival associations across molecular data types. ZNF718 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF718 RNA expression–survival associations across cancer types. High ZNF718 expression shows unfavorable associations in LUSC, LIHC, UCEC and UVM, but favorable associations in KIRC and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF718 RNA expression.
This table summarizes ZNF718 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF718. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF718 shows lower tumor expression in COAD, THCA, UCEC and READ and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher ZNF718 RNA expression in tumor versus normal tissue (log2 FC = +0.693, t-test p < 0.001).
This table shows molecular features associated with ZNF718 in patient tissues and cancer cell lines. In patient samples, ZNF718 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF718 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
